Plus   Neg

5 Top Gainers In Pharma Sector (SOLY, RWLK, VLRX...)

pharmaup may29 lt

The following are some of today's top gainers in the pharma/biotech sector.

1. Soliton Inc. (SOLY)

Gained 42.62% to close Wednesday's (May 29) trading at $20.28. This is the second straight day of gain.

News: The Company announced positive data from its proof of concept clinical trial of Rapid Acoustic Pulse (RAP) device in cellulite, and has decided to move forward with a pivotal trial.

The proof of concept clinical trial involved a study of five patients with moderate to severe cellulite, each treated on their thighs, with a new higher-powered version of Soliton's RAP device. This new higher-powered version of RAP device is not yet approved by the FDA.

The RAP device intended to assist in tattoo removal, which was cleared by the FDA on
May 28, 2019, is a different version.

The proof of concept clinical trial demonstrated a 20-47% improvement in cellulite severity score.

The pivotal cellulite study, which the Company has planned to conduct, will involve between 45 and 60 patients. The study is expected to begin within the next three months.

2. ReWalk Robotics Ltd. (RWLK)

Gained 37.37% to close Wednesday's trading at $4.08.

News: The Company's ReStore Exo-Suit for stroke rehabilitation has received CE marking, clearing it for sale to rehabilitation clinics in the European Union.

This CE Mark is the first clearance of a soft exo-suit, a next generation medical device which can serve a larger and more diverse patient population facing mobility challenges, according to the Company.

3. Valeritas Holdings Inc. (VLRX)

The Company is a maker of V-Go wearable insulin delivery device. V-Go won 510(k) clearance from the FDA in 2010 and CE Mark approval in the European Union in 2011.

Gained 37.32% to close Wednesday's trading at $3.90.

News: The company reiterated its second quarter 2019 revenue guidance of $7.4 Million to $7.6 million and its 2019 annual revenue guidance of $31.0 million to $34.0 million. Revenue was $6.5 million in the second quarter of 2018, and
$26.4 million in the full year of 2018.

The Company now expects to end the second quarter with $27 million in cash
and cash equivalents vs. the original estimate of $25 million. The cash on hand is expected to be sufficient to allow it to operate into February 2020, assuming no additional capital or non-dilutive financing.

4. Cara Therapeutics Inc. (CARA)

Gained 19.97% to close Wednesday's trading at $21.57.

News: The Company announced positive topline data from its pivotal Phase 3 trial of KORSUVA Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus, dubbed KALM-1.

5. InspireMD Inc. (NSPR)

InspireMD is a commercial-stage medical device company marketing
CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the
treatment of carotid artery disease, and MGuard Prime EPS in patients with coronary
artery disease.

Gained 12.61% to close Wednesday's trading at $3.84.

News: No news

Recent event:

On May 14, 2019, the Company announced financial results for the first quarter
ending March 31, 2019.

For the three months ended March 31, 2019, revenue was $415,000, representing a decrease of 59% from the comparable period in 2018, due to decrease in sales of CGuard EPS. Net loss for the first quarter of 2019 was $3.21 million or $3.82 per share compared to a net loss of $2.39 million or $54.00 per share for the same period in 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT